Diastolic heart failure in dialysis patients: Mechanisms, diagnostic approach, and treatment

Seminars in Dialysis

Volumn 25, Issue 1, 2012, Pages 35-41

  Pecoits Filho, Roberto ^a   Bucharles, Sérgio ^a   Barberato, Silvio H ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

LOOP DIURETIC AGENT; VASODILATOR AGENT;

CHRONIC KIDNEY FAILURE; DIASTOLIC HEART FAILURE; DOPPLER ECHOCARDIOGRAPHY; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE PRESSURE; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

ECHOCARDIOGRAPHY, DOPPLER; GLOMERULAR FILTRATION RATE; HEART CATHETERIZATION; HEART FAILURE, DIASTOLIC; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STROKE VOLUME; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 84856286989     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.01011.x     Document Type: Review

References (63)

1. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289(2):194-202, 2003.
2. Glassock RJ, Pecoits-Filho R, Barberato SH: Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4(Suppl 1):S79-S91, 2009.
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10(10):933-989, 2008.
4. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251-259, 2006.
5. Barberato SH, Pecoits Filho R: Prognostic value of left atrial volume index in hemodialysis patients. Arq Bras Cardiol 88(6):643-650, 2007.
6. London GM: Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 17(Suppl 1):29-36, 2002.
7. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27(3):347-354, 1996.
8. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36(2):286-290, 1989.
9. Tyralla K, Amann K: Morphology of the heart and arteries in renal failure. Kidney Int Suppl 63(84):S80-S83, 2003.
10. Diez J, Laviades C: Hypertensive heart disease in the patient with chronic kidney disease. Nefrologia 28(2):135-142, 2008.
11. Lopez B, Gonzalez A, Hermida N, Laviades C, Diez J: Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int Suppl 74(111):S19-S23, 2008.
12. Laviades C, Varo N, Diez J: Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 36(4):517-522, 2000.
13. Cottone S, Nardi E, Mule G, Vadala A, Lorito MC, Riccobene R, Palermo A, Arsena R, Guarneri M, Cerasola G: Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol 67(4):209-216, 2007.
14. Ortega O, Gallar P, Munoz M, Rodriguez I, Carreno A, Ortiz M, Molina A, Oliet A, Lozano L, Vigil A: Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in pre-dialysis patients. Nephron Clin Pract 97(4):c125-c130, 2004.
15. Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S: Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol 8(11):1764-1770, 1997.
16. Sato A, Funder JW, Saruta T: Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 12(9 Pt 1):867-873, 1999.
17. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28(1):53-61, 1996.
18. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15(8):2208-2218, 2004.
19. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87(7):E10-E17, 2000.
20. Amann K, Tornig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63(4):1296-1301, 2003.
21. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56(2):383-392, 1999.
22. Amann K, Ritz E, Wiest G, Klaus G, Mall G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4(10):1814-1819, 1994.
23. Cuppari L, Garcia-Lopes MG: Hypovitaminosis D in chronic kidney disease patients: prevalence and treatment. J Ren Nutr 19(1):38-43, 2009.
24. Bucharles S, Barberato SH, Stinghen AE, Gruber B, Meister H, Mehl A, Piekala L, Dambiski AC, Souza A, Olandoski M, Pecoits-Filho R: Hypovitaminosis D is associated with systemic inflammation and concentric myocardial geometric pattern in hemodialysis patients with low iPTH levels. Nephron Clin Pract 118(4):c384-c391, 2011.
25. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo Jr. CA, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72(8):1004-1013, 2007.
26. Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V, Espe K, Dekker F, Brandenburg V, Marz W, Ritz E, Wanner C: Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 31(18):2253-2261, 2010.
27. Andress DL: Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69(1):33-43, 2006.
28. Achinger SG, Ayus JC: The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int Suppl 67(95):S37-S42, 2005.
29. Valdivielso JM, Ayus JC: Role of vitamin D receptor activators on cardiovascular risk. Kidney Int Suppl 74(111):S44-S49, 2008.
30. Aranda RA, Pecoits-Filho RF, Romao JE Jr, Kakehashi E, Sabbaga E, Marcondes M, Abensur H: Kt/V in children on CAPD: how much is enough? Perit Dial Int 19(6):588-590, 1999.
31. Malik J, Tuka V, Mokrejsova M, Holaj R, Tesar V: Mechanisms of chronic heart failure development in end-stage renal disease patients on chronic hemodialysis. Physiol Res 58(5):613-621, 2009.
32. Barberato SH, Bucharles SG, Sousa AM, Costantini CO, Costantini CR, Pecoits-Filho R: Prevalence and prognostic impact of diastolic dysfunction in patients with chronic kidney disease on hemodialysis. Arq Bras Cardiol 94(4):457-462, 2010.
33. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10(7):1606-1615, 1999.
34. Barberato SH, Misocami M, Pecoits-Filho R: Association between left atrium enlargement and intradialytic hypotension: role of diastolic dysfunction in the hemodynamic complications during hemodialysis. Echocardiography 26(7):767-771, 2009.
35. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28(20):2539-2550, 2007.
36. Ferreira-Martins J, Leite-Moreira AF: Physiologic basis and pathophysiologic implications of the diastolic properties of the cardiac muscle. J Biomed Biotechnol 2010:1-12, 2010.
37. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22(2):107-133, 2009.
38. Barberato SH, Mantilla DE, Misocami MA, Goncalves SM, Bignelli AT, Riella MC, Pecoits-Filho R: Effect of preload reduction by hemodialysis on left atrial volume and echocardiographic Doppler parameters in patients with end-stage renal disease. Am J Cardiol 94(9):1208-1210, 2004.
39. Barberato SH, Pecoits Filho R: Influence of preload reduction on Tei index and other Doppler echocardiographic parameters of left ventricular function. Arq Bras Cardiol 86(6):425-431, 2006.
40. Sharma R, Pellerin D, Gaze DC, Mehta RL, Gregson H, Streather CP, Collinson PO, Brecker SJ: Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease. J Am Soc Echocardiogr 19(3):266-273, 2006.
41. Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM: Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol 41(6):1036-1043, 2003.
42. Pecoits-Filho R, Barberato SH: Echocardiography in chronic kidney disease: diagnostic and prognostic implications. Nephron Clin Pract 114(4):c242-c247, 2010.
43. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R: Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 53(18):1621-1628, 2009.
44. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14):e391-e479, 2009.
45. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P: Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol 4(4):755-762, 2009.
46. Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G: Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 97(3):383-388, 2004.
47. Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y: Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant 21(9):2507-2512, 2006.
48. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL: Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105(21):2512-2517, 2002.
49. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN: Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 54(6):505-512, 2009.
50. Tian J, Shidyak A, Periyasamy SM, Haller S, Taleb M, El-Okdi N, Elkareh J, Gupta S, Gohara S, Fedorova OV, Cooper CJ, Xie Z, Malhotra D, Bagrov AY, Shapiro JI: Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension 54(6):1313-1320, 2009.
51. Habibi J, Demarco VG, Ma L, Pulakat L, Rainey WE, Whaley-Connell AT, et al.: Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol 300(4):H1484-H1491, 2011.
52. Saudan P, Mach F, Perneger T, Schnetzler B, Stoermann C, Fumeaux Z, Rossier M, Martin PY: Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 18(11):2359-2363, 2003.
53. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16(4):1115-1125, 2005.
54. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33(1):73-81, 1999.
55. Lemmila S, Saha H, Virtanen V, Ala-Houhala I, Pasternack A: Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 18(5):404-410, 1998.
56. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM: Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45(6):1026-1033, 2005.
57. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ: Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24(5):503-510, 2004.
58. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A: Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 5(5):905-911, 2010.
59. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J: Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 43(11):2028-2035, 2004.
60. Siedlecki AM, Jin X, Muslin AJ: Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 75(8):800-808, 2009.
61. Fagugli RM, Pasini P, Pasticci F, Ciao G, Cicconi B, Buoncristiani U: Effects of short daily hemodialysis and extended standard hemodialysis on blood pressure and cardiac hypertrophy: a comparative study. J Nephrol 19(1):77-83, 2006.
62. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al.: In-center hemodialysis six times per week versus three times per week. N Engl J Med 363(24):2287-2300, 2010.
63. Zoccali C: Left ventricular mass index as an outcome measure in clinical trials in dialysis patients: a word of caution. Am J Nephrol 33(4):370-372, 2011.